TP53 and breast cancer: Intraductal injection of the resulting virus (AAV-PT) into Cas9 rats led to tumors with a median latency of only 42 days, markedly faster than targeting either Tp53 or Pik3ca alone (Fig 1G), confirming the high synergy of these two most common breast cancer genes.